Press Releases

New York, NY. April 26, 2018. The Lupus Research Alliance today announced that the newly formed clinical affiliate Lupus Therapeutics will collaborate with the pharmaceutical company, Bristol-Myers Squibb (BMS), to conduct a global trial evaluating the novel investigational drug, BMS-986165, as a potential treatment for people with lupus. BMS-986165 is a highly selective inhibitor of Tyrosine kinase […] READ MORE

2018 Omnibus Budget Passed March 23 Grants Lupus Advocates’ Requests

March 23, 2018 The Omnibus Appropriations bill for Fiscal Year 2018 that passed today includes key provisions the Lupus Research Alliance and lupus advocates have worked for all year. Lupus advocates, participating just days before for our annual March Capitol Hill Day, had requested program funding for 2019 and had asked legislators to also finish […] READ MORE

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

February 21, 2018 Source: Press Release, National Institutes of Health NIH program to accelerate therapies for arthritis, lupus releases first datasets Collaborative effort provides important clues about potential research targets NEW YORK, NY. Feb. 21, 2018.  Datasets characterizing individual cells in rheumatoid arthritis and systemic lupus erythematosus disease tissue from the Accelerating Medicines Partnership for […] READ MORE

Lupus Research Alliance Announces New Grants For Translational Research

Jan. 10, 2018 Lupus Research Alliance Announces New Grants for Translational Research Seven Outstanding Investigators Chosen for Prestigious Lupus Research Grants The Lupus Research Alliance is proud to announce the recipients of its Target Identification in Lupus (TIL) grants designed to move research discoveries quickly from the laboratory to the patient’s bedside. Seven outstanding scientists […] READ MORE

Lupus Multi-Cultural Engagement Partnership

  The Lupus Research Alliance and the National Minority Quality Forum Announce Lupus Multi-Cultural Engagement Partnership NEW YORK, December 19, 2017 — The Lupus Research Alliance and the National Minority Quality Forum launched the Lupus Multi-Cultural Engagement Partnership at the recent inaugural meeting in New York City which was attended by 30 national experts and key […] READ MORE

Lupus Research Alliance’s Breaking Through Gala

Lupus Research Alliance Welcomes Steve Burke, Selena Gomez, Seth Meyers and Kelli O’Hara to Breaking through Lupus Gala Raises Over $3.2 Million for Lupus Research November 21, 2017 – New York, NY – The Lupus Research Alliance celebrated the 2017 Breaking through Lupus Gala to shed a spotlight on breakthroughs from the previous years, and […] READ MORE

Lupus Research Alliance Announces Awards to Uncover Causes of Lupus

Two Outstanding Scientists Recognized for Transformative Lupus Research Projects Nov. 09, 2017. The Lupus Research Alliance is proud to announce the 2017 recipients of the Dr. William E. Paul Distinguished Innovator Awards in Lupus and Autoimmunity. Michael Carroll, PhD, Children’s Hospital Boston, is studying why and how lupus attacks the brain and central nervous system […] READ MORE

Lupus Research Alliance Prompted Stelara® Study for Lupus

Lupus Research Alliance welcomes compelling new data, presented at the American College of Rheumatology (ACR) annual meeting that demonstrated significant benefit for lupus patients treated with Stelara® (ustekinumab), a prescription medicine from the Janssen Pharmaceutical Companies. Stelara® is not approved for the treatment of lupus, but is approved by the FDA for certain autoimmune diseases. Through its drug repurposing program, the Lupus Research Alliance first identified Stelara® as a potential treatment for lupus and encouraged Janssen to pursue testing for this use. READ MORE

NEW YORK, NY. October 31, 2017 — The Lupus Research Alliance (LRA) announced the first clinical trials to be conducted through the new Lupus Clinical Investigators Network (LuCIN). The LRA organized, manages and funds LuCIN to accelerate thef development of new lupus therapies. Comprising50+ top academic research centers throughout North America, LuCIN provides a framework to quickly […] READ MORE

Lupus Research Alliance Welcomes Self-Injectable Form of Belimumab

The Lupus Research Alliance congratulates GlaxoSmithKline (GSK) on the approval of belimumab (Benlysta®) by the U.S. Food and Drug Administration as a self-injectable (subcutaneous) formulation for people with systemic lupus erythematosus being treated with standard therapy. Belimumab is currently approved as a one-hour intravenous infusion given once every four weeks by a healthcare professional in […] READ MORE

Multi-ethnic Study Identifies New Genetic Markers for Lupus

Scientists from an international consortium have identified a large number of new genetic markers that predispose individuals to lupus. The study is published in the July 17 issue of the journal Nature Communications and was led by researchers at Wake Forest Baptist Medical Center, Oklahoma Medical Research Foundation, King’s College of London and Genentech Inc. Autoimmune diseases […] READ MORE

App developed by Lupus Research Alliance, Pfizer Inc. and Tata to be tested through non-interventional clinical trial called VALUE

NEW YORK, NY. May 9, 2017— The Lupus Research Alliance and global biopharmaceutical company Pfizer Inc.announced a non-interventional clinical study called VALUE (VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool), to test a custom smartphone app that allows lupus patients to report on their symptoms in real time. Incorporating feedback from people with lupus, the […] READ MORE